Movatterモバイル変換


[0]ホーム

URL:


WO1990010710A1 - Detection of pyrogens by recombinant mammalian cells - Google Patents

Detection of pyrogens by recombinant mammalian cells
Download PDF

Info

Publication number
WO1990010710A1
WO1990010710A1PCT/GB1990/000312GB9000312WWO9010710A1WO 1990010710 A1WO1990010710 A1WO 1990010710A1GB 9000312 WGB9000312 WGB 9000312WWO 9010710 A1WO9010710 A1WO 9010710A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell line
promoter
coding region
galactosidase
pyrogen
Prior art date
Application number
PCT/GB1990/000312
Other languages
French (fr)
Inventor
Enda Kenny
Original Assignee
Delta Biotechnology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Biotechnology LimitedfiledCriticalDelta Biotechnology Limited
Publication of WO1990010710A1publicationCriticalpatent/WO1990010710A1/en

Links

Classifications

Definitions

Landscapes

Abstract

A mammalian cell line having an inheritable genetic element comprising a TNF, IL-1α or IL-1β promoter and, under transcriptional control thereof, a coding region, wherein the promoter controls transcription of the coding region in response to the exposure of the said cell line to a pyrogen and the said coding region encodes a reporter polypeptide. The cell line is used as the basis of an assay. The promoter is preferably the human interleukin-1α or -1β promoter, the cell line is preferably human monocyte derived, and the reporter polypeptide may be β-galactosidase, α-galactosidase, chloramphenicol acetyl transferase, luciferase or phosphatase.

Description

DETECTION OF PYROGENS BY RECOMBINANT MAMMALIAN CELLS
This invention relates to assay systems for pyrogenic molecules which exert their effects through the transcriptional activation of genes.
At present, assay of such compounds may involve the treatment of specific mammalian cell lines with the test substance and the subsequent assay of the cell line for synthesis of the gene product known to be produced in response to the test agent. The assay and quantitation of the newly synthesised gene product in such a system is then an indicator of the amount of active material in the test substance.
Microbial contamination of parenterally administered therapeutic products commonly results in a pyrogenic reaction upon administration. Man is particularly sensitive to bacterial lipopolysaccharide (LPS) which, in even nanogram amounts, may induce fever. Pharmaceutical products which are intended for parenteral administration must therefore be screened for pyrogenic contaminants. The currently accepted methods for detecting pyrogens are the Limulus Amoebocyte Lysate (LAL) and the rabbit test. The LAL test is an in vitro test whilst the rabbit test directly measures the rise in body temperature in response to injection of the test substance. However, these tests are not definitive and at least one case of an E.coli derived recombinant product has been reported which was pyrogen negative in the above tests but which upon administration to man proved to be pyrogenic (Dinarello, et al. , 1985).
The febrile response is mediated by the release from monocytes of cytokines, such as tumour necrosis factor and interleukin 1 , which have a broad- range of biological effects. A refinement of the pyrogen test is the direct measurement of cytokines released by monocytes in vitro using immuno methods. The synthesis and release of both TNF and interleukin-1 by monocytes following treatment with LPS are well characterised (Dinarello, 1984; Phillip and Epstein, 1986) and a monocyte test for pyrogen has been developed based on these observations (Poole, et al. , 1988).
At least two distinct forms of interleukin 1 exist, termed IL-lα and IL-lβ (March, et al. , 1985). Of these, the IL-lβ gene is more responsive to LPS stimulation (Poole, et al. , 1988). Established monocytic cell lines are similarly responsive to LPS although the sensitivity of such cell lines is reportedly not as great as that of fresh monocyte preparations (Poole, et al. , 1988). Such detection methods, however, may be laborious and require the use of expensive reagents and equipment.
We have now found that such potential problems may be reduced by the replacement of the known induced gene product with an easily quantifiable reporter gene within the mammalian or other cell line normally used for assay. Thus the reporter gene is induced in response to the test sample and then easily quantified as outlined in the description following. Additionally, such new cell lines can have the advantage of increased sensitivity since response is proportional to the copy number of the cloned promoter-reporter gene fusion and this copy number can be made to be more than one.
Thus, one aspect of the present invention provides a mammalian cell line having an inheritable genetic element comprising a TNF, IL-lα or IL-lβ promoter and, under transcriptional control thereof, a coding region, wherein the promoter controls transcription of the coding region in response to the exposure of the said cell line to a pyrogen and the said coding region encodes a reporter polypeptide.
As used herein, the term "promoter" means a nucleotide sequence 5' to a TNF, IL-lα or IL-lβ coding region which controls transcription thereof; the promoter may comprise an enhancer system which may or may not be one normally associated with that promoter. The term "reporter polypeptide" is used to mean a polypeptide other than TNF, IL-lα or IL-lβ and which polypeptide can be detected by means other than (i) immunological techniques and (ii) means requiring a second living cell. A second aspect of the invention provides an assay system comprising a cell line having an inheritable genetic element comprising a TNF, IL-lα or IL-lβ promoter and, under transcriptional control thereof, a coding region, wherein the promoter controls transcription of the coding region in response to the exposure of the said cell line to a pyrogen and the said coding region encodes a reporter polypeptide.
A third aspect of the invention provides a vector for transfecting a cell line, the vector comprising a TNF, IL-lα or IL-lβ promoter and, under transcriptional control thereof, a coding region, wherein the promoter controls transcription of the coding region in response to the exposure of the said cell line to a pyrogen and the said coding region encodes a reporter polypeptide.
In a preferred embodiment of the invention, the cell line is derived from a human blood monocyte, such as the THP-1 and U937 cell lines. Preferably, the promoter is human-derived.
The reporter polypeptide is conveniently β-galactosidase, chloramphenicol acetyl transferase, luciferase, phosphatase or α-galactosidase. Transcriptional and translational start and stop codons and downstream regulatory regions may be included as necessary and in known ways.
Preferred embodiments of the present invention will now be described by way of example and with reference to the accompanying drawings, in which:
Figure 1 shows the partial sequence of the IL-lβ gene (from Bensi et al, 1987), with the exons boxed and the positions at which probes 1 and 2 hybridize also indicated;
Figure 2 illustrates schematically the subcloning of the IL-lβ promoter into plasmid ml3mp8 to form plasmid mp8.1;
Figure 3 illustrates schematically the site-directed mutagenesis of plasmid mp8.1 to give plasmid mpδ.1.1; and
Figure 4 illustrates schematically the construction of plasmid pEK007.
EXAMPLE 1 : A CELL LINE FOR DETECTION OF INTERLEUKIN lβ SYNTHESIS
Outline
The IL-lβ gene promoter is fused to the lacZ gene of E.coli which encodes β-galactosidase and this cassette is inserted into a suitable cell line. Stimulation of this cell line by LPS or other pyrogen will result in the synthesis of β-galactosidase which may then be detected in a simple colorimetric assay. Thus pyrogen may be measured indirectly, obviating the requirement for the relatively complex, time consuming and expensive immunological techniques used in the direct detection of TNF and IL-lβ. The construction of such a cell line is given below. The molecular biological techniques are generally those taught by Maniatis et al, 1982.
Isolation of the IL-lβ Gene Promoter
A human leukocyte genomic DNA bank in the vector EMBL3 may be obtained from Clontech Laboratories Inc. (Palo Alto, California). The sequence of the 5' end of the IL-lβ gene is shown in Figure 1 (Bensi et al. , 1987). Oligonucleo ide probes which hybridize to the positions underlined in Figure 1 are constructed on an automatic DNA synthesiser using phosphoramidite chemistry and reagents supplied by the manufacturer (Applied Biosystems, Foster City, California). These structures are as follows:
Probe 1
G A C C A C A T T A A A A T A C T G G A T T T T C C C A C G
Probe 2
C A G G T A C T T C T G C C A T G G C T G C T T C A G A C A C
These oligonucleotides are labelled with ^2P and used to probe the gene bank by plaque hybridization as described by Maniatis et al. , (1982).
Positive clones, those hybridizing to both primers, are further characterized by restriction mapping and comparison with the published restriction data available via analysis of the DNA sequence described previously (Bensi et al. , 1987). In this way the sequence may be extended 5' to that reported by Bensi et a^ (1987) and the upstream sequence encompassing the promoter or regulatory regions isolated. This is most probably located in a region extending to 3kb 5' from the transcription start site. Next the insert or partial insert of the EMBL-3 clone which spans the desired sequence is subcloned into M13mp8 (Messing, 1983). This is carried out by insertion of a blunt-ended DNA fragment into the BamHI site of M13mp8 which has been similarly blunt-ended as described previously (GB-A-2175590) as shown in Fig 2. A clone (designated mp8.1) is chosen in which exon 2 is adjacent to the Sail site of mp8.
Next, mp8.1 is manipulated to create a Bglll site in exon 2 which is compatible with the tailored β-galactosidase gene from plasmid pMC1924 (Nielsen et al, 1983). This is most readily carried out by changing two nucleotides in exon 2 as shown in Fig 3 using the technique of oligonucleotide-directed mutagenesis (Zoller and Smith, 1983) to create xαpδ.l.l.
The lL-lβ promoter-N-terminus is now located on a Smal-Bglll fragment, the Smal site being derived from M13mp8. This fragment is then cloned into PvuII/BamHI digested pMC1924 (Nielsen et al, 1983) to give the plasmid pEK007 (Fig 4).
The E. coli β-galactosidase gene has been tailored in pMC1924 such that insertion of the above fragment will result in an in- frame fusion of the IL-lβ-N-terminus and β-galactosidase. The fusion will have β-galactosidase enzyme activity. Transfection of Cell Line
The recombinant pMC1924 derivative containing the interleukin-lβ promoter, pEK007, is next transferred into a suitable cell line such as THP-1 (Fenton, et al. , 1987) as described by Gorman (1985). Stable integrant clones are obtained via co- transfection of pSVNeo, encoding resistance to the aminoglycoside G418 (Southern and Berg, 1982). Co-integrants of pSVNeo and pEK007 are screened for by resistance to G418 and subsequent Southern blotting of G418 resistance clones for co- insertion of the β-galactosidase gene using the β-galactosidase gene as a probe, as described by Maniatis et al. , (1982).
Induction of β-Galactosidase Synthesis
The transgenic THP-1 cell line is next induced with LPS as described in Fenton et al. (1987). β-galactosidase may be assayed as described by Gorman (1985) and Nielsen (1983). Analysis of LPS-stimulated clones shows that β-galactosidase is produced and the amount produced corresponds with the degree of stimulation. It is probable that cell lines with different copy numbers of integrated pEK007 will exhibit slightly different responses, with the degree of responsiveness and thus sensitivity being proportional to the number of integrated copies of the plasmid. Following these analyses, a suitable sub-line is chosen as the basis for the pyrogen assay and its response to a range of pyrogens in addition to LPS assessed. Additional Expression Signals
Some mammalian and higher eukaryotic genes have additional expression regulatory elements within the gene itself or in the 3' non-coding region. There may well be such additional elements within the interleukin lβ gene. Thus expression of the hybrid interleukin Iβ:β-galactosidase fusion polypeptide may require such additional signals. If therefore LPS failed to stimulate β-galactosidase synthesis, selected regions such as the 3' non-coding region of the interleukin lβ gene may be attached to the fusion and the effect of these assessed.
A typical assay kit using a cell line of the invention may be supplied as a microtitre plate containing a sample of the cell line and the substrate for β-galactosidase (X-gal) in each well along with cell culture medium and other essential factors. The plate may be supplied frozen and would be thawed prior to use and addition of the test sample to the culture dish well. Incubation at 37°C in a suitable incubator will proceed for a period of time sufficient for the pyrogen contained with the test sample to stimulate β-galactosidase expression and sufficient chromophore to be generated to facilitate its measurement in a plate-reading spectrophotometer. The signal generated may finally be compared to that generated by known amounts of pyrogen in a parallel standard assay and thus the amount of pyrogen in the test sample assessed. FURTHER EXAMPLES
Alternative Promoters and Reporter Genes
The effector cytokines for the pyrogenic response are believed to be TNF, IL-lβ and IL-lα; however additional factors may be involved. Thus, TNF and IL-lα gene promoters are alternative promoters in this system. Similarly there are other simple reporter genes such as chloramphenicol acetyl transferase (CAT), horseradish peroxidase, luciferase and phosphatase which may be substituted for β-galactosidase to facilitate detection of cytokine synthesis. Gorman (1985), section 7.1, details an assay for CAT, whilst Van Zonneveld et al (1988) detail an assay for luciferase.
REFERENCES
Bensi, G. , et al. , (1987) Gene, 52; 95-101.
Dinarello, CA. (1984) Rev.Infect.Pis. 6; 51-95.
Dinarello, CA. , et al. , (1985) J.Clin.Microbiol, 20; 323-329.
Fenton, M.J., et al. , (1987) J.Immunol, 138; 3972-3979.
Gorman, C (1985) in "DNA Cloning Vol II". Glover, D.M. (Ed) 143-189 IRL Press Oxford.
Maniatis, T. , et al. , (1982) Molecular Cloning : A laboratory- manual. Cold Spring Harbor Publications, N.Y. U.S.A.
March, C.J. et al. , (1985) Nature. 315; 641-647.
Messing, J. (1983) Methods in Enzymol. 100, 20-78.
Nielsen, D.A. , et al. , (1983) Proc. Natl. Acad. Sci (USA). 80; 5198-5202.
Phillip, R. and Epstein, L. (1986) Nature. 323, 86-89.
Poole, S., et al. , (1988) Lancet. I, 130. Van Zonneveld, A-J. , Curriden, S.A. and Loskutoff, D.J. (1988) Proc. Natl. Acad. Sci. USA. 85; 5525-5529.
Zoller, M.J. and Smith M. (1983) Methods in Enzymol. 100; 468- 500.

Claims

1. A mammalian cell line having an inheritable genetic element comprising a TNF, IL-lα or IL-lβ promoter and, under transcriptional control thereof, a coding region, wherein the promoter controls transcription of the coding region in response to the exposure of the said cell line to a pyrogen and the said coding region encodes a reporter polypeptide.
2. A cell line according to Claim 1 wherein the cell line is adapted to detect the presence of microbial endotoxin.
3. A cell line according to Claim 1 or 2 wherein the cell line is derived from a monocyte.
4. A cell line according to any one of the preceding claims wherein the promoter is human derived.
5. A cell line according to any one of the preceding claims wherein the reporter polypeptide is β-galactosidase, chloramphenicol acetyl transferase, luciferase, a phosphatase or α-galactosidase.
6. An assay system comprising a cell line according to any one of the preceding claims.
7. A vector for transfecting a cell line, the vector comprising a TNF, IL-lα or IL-lβ promoter and, under transcriptional control thereof, a coding region, wherein the promoter controls transcription of the coding region in response to the exposure of the said cell line to a pyrogen and the said coding region encodes a reporter polypeptide.
PCT/GB1990/0003121989-03-091990-02-28Detection of pyrogens by recombinant mammalian cellsWO1990010710A1 (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
GB898905394AGB8905394D0 (en)1989-03-091989-03-09Detection of certain molecules
GB8905394.61989-03-09

Publications (1)

Publication NumberPublication Date
WO1990010710A1true WO1990010710A1 (en)1990-09-20

Family

ID=10653014

Family Applications (1)

Application NumberTitlePriority DateFiling Date
PCT/GB1990/000312WO1990010710A1 (en)1989-03-091990-02-28Detection of pyrogens by recombinant mammalian cells

Country Status (5)

CountryLink
AU (1)AU5160690A (en)
CA (1)CA2011799A1 (en)
GB (1)GB8905394D0 (en)
IL (1)IL93592A0 (en)
WO (1)WO1990010710A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP0496027A1 (en)*1991-01-251992-07-29R.O.B.I.T. RESEARCH AND DEVELOPMENT COMPANY LTD., c/o EFRATI, GALILI & CO.A bioluminescence assay for gene expression in growing mammalian cells
EP0516443A1 (en)*1991-05-311992-12-02Eli Lilly And CompanyVectors and methods for assaying the regulation of apolipoprotein ai synthesis
EP0519336A3 (en)*1991-06-181993-04-28Boehringer Ingelheim International G.M.B.H.Chimeric gene comprising a promoter-regulater and a gene coding for an indicator protein
WO1994017208A1 (en)*1993-01-211994-08-04President And Fellows Of Harvard CollegeMethods and diagnostic kits utilizing mammalian stress promoters to determine toxicity of a compound
US5958707A (en)*1991-10-031999-09-28Schering CorporationHuman interleukin-4 antagonist/agonist screens
WO2002052039A3 (en)*2000-12-272004-02-19Geneka Biotechnology IncMethods for selecting and producing pharmaceutical compounds using a library responsive to transcription factors
CN108707626A (en)*2018-04-102018-10-26中国科学院微生物研究所A kind of preparation method of the monoclonal cell system of detectable pyrogen
CN111484980A (en)*2020-03-182020-08-04上海市食品药品检验所Monoclonal cell strain, construction method thereof and application thereof in pyrogen assay

Citations (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP0062237A1 (en)*1981-03-251982-10-13Yeda Research And Development Company, Ltd.Process for the determination of the carcinogenicity of chemical or physical agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP0062237A1 (en)*1981-03-251982-10-13Yeda Research And Development Company, Ltd.Process for the determination of the carcinogenicity of chemical or physical agents

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, volume 101, no. 20, 12 November 1984, (Columbus, Ohio, US), Dinarello, Charles A et al : "Human leukocytic pyrogen test for detection of pyrogenic material in growth hormone produced by recombinant Escherichia coli", see page 400, abstract 177607h, & J.Clin.Microbiol. 1984, 20( 3), 323- 32*
Chemical Abstracts, volume 101, no. 26, 24 December 1984, (Columbus, Ohio, US), Henne, Werner et al : "Hollow-fiber dialyzers and their pyrogenicity testing by Limulus amebocyte lysate", see page 305, abstract 235513n, & Artif.Organs 1984, 8( 3), 299- 30*
Chemical Abstracts, volume 109, no. 15, 10 October 1988, (Columbus, Ohio, US), Karube, Isao et al : "Development of immuno-sensor system for determination of pyrogens", see page 329, abstract 125177p, & Kenkyu Hokoku-Asahi Garasu Kogyo Gijutsu 1987, 51(), 301- 30*
Chemical Abstracts, volume 111, no. 8, 21 August 1989, (Columbus, Ohio, US), Lee, Beom Jun et al : "Influence of low or high endotoxin-susceptible rabbit on pyrogen test", see page 400, abstract 64042h, & Korean J. Toxicol. 1988, 4( 2), 181- 18*
Chemical Abstracts, volume 96, no. 3, 18 January 1982, (Columbus, Ohio, US), Boobis, Susan et al : "Measurement of hypozincemia in mice:a sensitive test for detection of pyrogens", see page 76, abstract 15678h, & Clin.Sci. 1981, 61( 4), 445- 44*
Dialog Information Services, File 154, Medline 83- 90, Dialog accession no. 89137759, Poole S et al: "Assay of pyrogenic contamination in pharmaceuticalsby cytokine release from monocytes", Dev Biol Stand 1988, 69 p 121-3*

Cited By (12)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP0496027A1 (en)*1991-01-251992-07-29R.O.B.I.T. RESEARCH AND DEVELOPMENT COMPANY LTD., c/o EFRATI, GALILI & CO.A bioluminescence assay for gene expression in growing mammalian cells
EP0516443A1 (en)*1991-05-311992-12-02Eli Lilly And CompanyVectors and methods for assaying the regulation of apolipoprotein ai synthesis
EP0519336A3 (en)*1991-06-181993-04-28Boehringer Ingelheim International G.M.B.H.Chimeric gene comprising a promoter-regulater and a gene coding for an indicator protein
JP3372267B2 (en)1991-06-182003-01-27ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Chimeric gene
US5958707A (en)*1991-10-031999-09-28Schering CorporationHuman interleukin-4 antagonist/agonist screens
US6200805B1 (en)1991-10-032001-03-13Schering CorporationMaterials and methods for screening human interleukin-4 antagonists/agonists
WO1994017208A1 (en)*1993-01-211994-08-04President And Fellows Of Harvard CollegeMethods and diagnostic kits utilizing mammalian stress promoters to determine toxicity of a compound
US5811231A (en)*1993-01-211998-09-22Pres. And Fellows Of Harvard CollegeMethods and kits for eukaryotic gene profiling
WO2002052039A3 (en)*2000-12-272004-02-19Geneka Biotechnology IncMethods for selecting and producing pharmaceutical compounds using a library responsive to transcription factors
CN108707626A (en)*2018-04-102018-10-26中国科学院微生物研究所A kind of preparation method of the monoclonal cell system of detectable pyrogen
CN108707626B (en)*2018-04-102021-10-01中国科学院微生物研究所 A kind of preparation method of monoclonal cell line capable of detecting pyrogen
CN111484980A (en)*2020-03-182020-08-04上海市食品药品检验所Monoclonal cell strain, construction method thereof and application thereof in pyrogen assay

Also Published As

Publication numberPublication date
AU5160690A (en)1990-10-09
IL93592A0 (en)1990-12-23
GB8905394D0 (en)1989-04-19
CA2011799A1 (en)1990-09-09

Similar Documents

PublicationPublication DateTitle
Heeger et al.Isolation and characterization of cDNA from renal tubular epithelium encoding murine Rantes
Weiss et al.Nuclear factor of activated T cells is associated with a mast cell interleukin 4 transcription complex
Imler et al.A Harvey-ras responsive transcription element is also responsive to a tumour-promoter and to serum
Emmel et al.Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation
D'Alfonso et al.Systemic lupus erythematosus candidate genes in the Italian population: Evidence for a significant association with interleukin‐10
Umemori et al.Initial events of myelination involve Fyn tyrosine kinase signalling
Jain et al.The AP-1 site at-150 bp, but not the NF-kappa B site, is likely to represent the major target of protein kinase C in the interleukin 2 promoter.
Kubo et al.T‐cell subset‐specific expression of the IL‐4 gene is regulated by a silencer element and STAT6
Srivastava et al.Estrogen blocks M-CSF gene expression and osteoclast formation by regulating phosphorylation of Egr-1 and its interaction with Sp-1.
KRUSE et al.The polymorphisms S503P and Q576R in the interleukin‐4 receptor α gene are associated with atopy and influence the signal transduction
Liu et al.Cyclosporin A‐sensitive induction of the Epstein‐Barr virus lytic switch is mediated via a novel pathway involving a MEF2 family member
Lütticken et al.Interleukin-6-induced serine phosphorylation of transcription factor APRF: evidence for a role in interleukin-6 target gene induction
Dong et al.The Smad3 protein is involved in TGF-β inhibition of class II transactivator and class II MHC expression
Murphy et al.Role of the Stat4 N domain in receptor proximal tyrosine phosphorylation
Tsukada et al.A novel STAT-like factor mediates lipopolysaccharide, interleukin 1 (IL-1), and IL-6 signaling and recognizes a gamma interferon activation site-like element in the IL1B gene
Li et al.Characterization of the human pleiotrophin gene. Promoter region and chromosomal localization.
Zhang et al.Regulation of the activity of IFN-γ promoter elements during Th cell differentiation
Cockerill et al.Regulation of GM-CSF gene transcription by core-binding factor
Berberich‐Siebelt et al.C/EBPβ enhances IL‐4 but impairs IL‐2 and IFN‐γ induction in T cells
WO1990010710A1 (en)Detection of pyrogens by recombinant mammalian cells
Alexandropoulos et al.v-Fps-responsiveness in the Egr-1 promoter is mediated by serum response elements
Shukla et al.Transforming growth factor beta increases the expression of HIV-1 gene in transfected human mesangial cells
Linker-Israeli et al.A greater variability in the 3′ flanking region of the IL-6 gene in patients with systemic lupus erythematosus (SLE)
Fugger et al.IL‐6 gene polymorphism in rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis, systemic lupus erythematosus, and in healthy Danes
Tara et al.Characterization of the constitutive and inducible components of a T cell IL-4 activation responsive element.

Legal Events

DateCodeTitleDescription
AKDesignated states

Kind code of ref document:A1

Designated state(s):AU FI HU JP KR US

ALDesignated countries for regional patents

Kind code of ref document:A1

Designated state(s):AT BE CH DE DK ES FR GB IT LU NL SE


[8]ページ先頭

©2009-2025 Movatter.jp